Search research articles
Contact Us
Filters
Showing results (61-70 of 111) with videos related to
Page
of 12
Sort By:
Journal of Managed Care & Specialty Pharmacy
|
August 1, 2024
Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States
Oralee J Varnado, Michelle Vu, Erin Buysman, et al.
Headache
|
June 20, 2024
A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States
Shivang Joshi, Andrew Spargo, Margaret Hoyt, et al.
The Oncologist
|
June 21, 2023
A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis
Marie Fallon, Maciej Sopata, Erika Dragon, et al.
International Journal of Clinical Practice
|
October 9, 2021
Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials
Francis Berenbaum, Thomas Schnitzer, Alan Kivitz, et al.
The World Journal of Men'S Health
|
May 30, 2014
The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis
Sung Won Lee, Jae Seung Paick, Hyun Jun Park, et al.
Advances in Therapy
|
August 12, 2022
Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis
Thomas J Schnitzer, Gianluca Bonfanti, Joanna Atkinson, et al.
European Urology
|
August 30, 2011
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial
Hartmut Porst, Edward D Kim, Adolfo R Casabé, et al.
The Journal of Urology
|
October 8, 2013
Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies
Gerald B Brock, Kevin T McVary, Claus G Roehrborn, et al.
Headache
|
September 29, 2025
Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
Richard B Lipton, Miguel J A Láinez, Zubair Ahmed, et al.
Current Medical Research and Opinion
|
February 9, 2024
Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study
Oralee J Varnado, Michelle Vu, Erin K Buysman, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 111) with videos related to
Sort By:
Page
of 12
Journal of Managed Care & Specialty Pharmacy
|
August 1, 2024
Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States
Oralee J Varnado, Michelle Vu, Erin Buysman, et al.
Headache
|
June 20, 2024
A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States
Shivang Joshi, Andrew Spargo, Margaret Hoyt, et al.
The Oncologist
|
June 21, 2023
A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis
Marie Fallon, Maciej Sopata, Erika Dragon, et al.
International Journal of Clinical Practice
|
October 9, 2021
Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials
Francis Berenbaum, Thomas Schnitzer, Alan Kivitz, et al.
The World Journal of Men'S Health
|
May 30, 2014
The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis
Sung Won Lee, Jae Seung Paick, Hyun Jun Park, et al.
Advances in Therapy
|
August 12, 2022
Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis
Thomas J Schnitzer, Gianluca Bonfanti, Joanna Atkinson, et al.
European Urology
|
August 30, 2011
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial
Hartmut Porst, Edward D Kim, Adolfo R Casabé, et al.
The Journal of Urology
|
October 8, 2013
Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies
Gerald B Brock, Kevin T McVary, Claus G Roehrborn, et al.
Headache
|
September 29, 2025
Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
Richard B Lipton, Miguel J A Láinez, Zubair Ahmed, et al.
Current Medical Research and Opinion
|
February 9, 2024
Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study
Oralee J Varnado, Michelle Vu, Erin K Buysman, et al.
Page
of 12